Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Silmitasertib |
| Synonyms | |
| Therapy Description |
Silmitasertib (CX-4945) inhibits protein kinase CK2 (CSNK2), potentially resulting in decreased growth of tumor cells, alone and in combination with other agents (PMID: 21159648, PMID: 27758824, PMID: 32615532). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Silmitasertib | CX-4945|CX4945|CX 4945 | Silmitasertib (CX-4945) inhibits protein kinase CK2 (CSNK2), potentially resulting in decreased growth of tumor cells, alone and in combination with other agents (PMID: 21159648, PMID: 27758824, PMID: 32615532). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03904862 | Phase Ib/II | Silmitasertib | Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery | Terminated | USA | 0 |
| NCT03897036 | Phase I | Silmitasertib | Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) | Completed | USA | 0 |